New drugs appearance

An update of the comparison of NCEs marketed in the U.S. and Britain from January 1972 through December 1976 indicated that in this five-year period 82 new drugs appeared for the first time in one or both of the two countries.(23) Of these, only 29% became mutually available in both countries—2.4 times as many becoming available first in Britain as in the U.S. Of the 71% that became exclusively available, 2.6 times as many became available in Britain as in the U.S. 

Phase II consists of small trials in individuals with the illness to be treated (usually trials of 24 to 300 persons). The goals of Phase II trials are to provide either a proof of mechanism or a proof of the hypothesized therapeutic concept, identify the patient population(s) in which the new drug appears to work, and determine an appropriate dose regimen for subsequent large-scale trials. Dose regimen includes the loading dose, maintenance dose, dose frequency, dose duration, and dose adjustments for special populations and for coadministration with other drugs. 

Although rifaximin has stood the test of time, it still attracts the attention of both basic scientists and clinicians as attested by the regular number of publications which appear every year in the medical literature (fig. 10). As a matter of fact, with the advancement of the knowledge on microbial-gut interactions in health and disease novel indications and new drug regimens are being explored. 

The first steps in unravelling the details of an unknown system frequently involve the identification of its constituents by qualitative chemical analysis. Follow-up investigations usually require structural information and quantitative measurements. This pattern appears in such diverse areas as the formulation of new drugs, the examination of meteorites, and studies on the results of heavy ion bombardment by nuclear physicists. 

The initial stage of drug release from the formulation, both in terms of the amount and the rate of release, may exercise considerable influence at the clinical response level. A close consideration of the formulation parameters of any chemical is therefore essential during the development of any new drug, and, indeed, there are examples where formulations of established drugs also appear to require additional investigation. 

One major difficulty has been that no convincing laboratory model of the drug s clinical effect has yet been established. This has not only hampered mechanistic investigations but has also prevented the rational search, by medicinal chemists, for more specifically effective anti-hypertensive 3-blocking agents. New drug candidates appear to have been selected on the basis of the laboratory pharmacological profile of the molecule and how this profile relates to one or other of the various mode-of-... 

Surprisingly, it appeared that there had been hardly any therapeutic progress in the management of belladonna poisoning since the 19 century, when opium was the most commonly used treatment. The first six decades of the 20 century spawned many new drugs, but no one seemed to have reported anything good for atropine delirium in mainstream medical journals. 

---